Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-34,000
Closed -$13.8K 15319
2025
Q1
$13.8K Sell
34,000
-11,200
-25% -$7.18K ﹤0.01% 13388
2024
Q4
$29.9K Sell
45,200
-40,100
-47% -$27.9K ﹤0.01% 12880
2024
Q3
$72.4K Buy
85,300
+12,100
+17% +$9.25K ﹤0.01% 11509
2024
Q2
$48.8K Buy
73,200
+47,300
+183% +$39.3K ﹤0.01% 11787
2024
Q1
$33.7K Buy
25,900
+7,100
+38% +$7.44K ﹤0.01% 12577
2023
Q4
$10.8K Sell
18,800
-600
-3% -$415 ﹤0.01% 13086
2023
Q3
$14.6K Sell
19,400
-1,000
-5% -$761 ﹤0.01% 12864
2023
Q2
$14.9K Buy
20,400
+3,500
+21% +$3.25K ﹤0.01% 12978
2023
Q1
$12.8K Sell
16,900
-11,600
-41% -$10.8K ﹤0.01% 13391
2022
Q4
$27.4K Sell
28,500
-15,300
-35% -$21.6K ﹤0.01% 12842
2022
Q3
$95K Sell
43,800
-15,800
-27% -$54.5K ﹤0.01% 11138
2022
Q2
$209K Buy
59,600
+7,500
+14% +$28K ﹤0.01% 10615
2022
Q1
$263K Sell
52,100
-19,300
-27% -$97.8K ﹤0.01% 10896
2021
Q4
$448K Sell
71,400
-41,900
-37% -$286K ﹤0.01% 9968
2021
Q3
$901K Sell
113,300
-250,600
-69% -$2.06M ﹤0.01% 8423
2021
Q2
$2.73M Buy
363,900
+212,200
+140% +$1.48M ﹤0.01% 5840
2021
Q1
$918K Sell
151,700
-70,800
-32% -$545K ﹤0.01% 8337
2020
Q4
$1.27M Buy
222,500
+19,500
+10% +$124K ﹤0.01% 6285
2020
Q3
$1.35M Buy
+203,000
New +$1.81M ﹤0.01% 5470

Other funds holding VXRT

Citadel Advisors's VXRT Position: Q1 2025 in Review

Citadel Advisors sold out of Vaxart (VXRT) in Q1 2025, closing a stake of 501,623 shares — an estimated $322K sold.

Citadel Advisors first reported a position in VXRT in Q1 2014 and held it in 23 quarters. The position peaked at $27.4M in Q2 2020. 92 funds tracked by Wall St. Rank hold VXRT as of Q1 2025.

  • Citadel Advisors reported no remaining Vaxart position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 501,623 Vaxart shares in Q1 2025, an estimated $322K.
  • Citadel Advisors first reported a position in Vaxart in Q1 2014 and held it in 23 quarters.
  • Citadel Advisors's Vaxart position peaked at $27.4M in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Vaxart as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.